Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Macarthur

Showing results (121-130 of 151) with videos related to

Pageof 16
Sort By:
Cell Reports|November 15, 2018
Thrombopoietin Metabolically Primes Hematopoietic Stem Cells to Megakaryocyte-Lineage DifferentiationAyako Nakamura-Ishizu, Takayoshi Matsumura, Patrick S Stumpf, et al.
AIDS Research and Human Retroviruses|October 13, 2020
Micro RNA Targets in HIV Latency: Insights into Novel Layers of Latency ControlAshley I Heinson, Jeongmin Woo, Amey Mukim, et al.
Frontiers in Immunology|October 7, 2022
Transcriptional programming of immunoregulatory responses in human Langerhans cellsJames Davies, Sofia Sirvent, Andres F Vallejo, et al.
HIV Clinical Trials|February 1, 2005
Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive personsR D MacArthur, L Chen, G Peng, et al.
Pharmacogenetics|April 13, 2000
Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotypeW M O'Neil, R K Drobitch, R D MacArthur, et al.
HIV Clinical Trials|December 17, 2013
Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage studyRodger D Macarthur, Trevor N Hawkins, Stephen J Brown, et al.
Controlled Clinical Trials|April 18, 2001
The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trialR D MacArthur, L Chen, D L Mayers, et al.
Nature|August 13, 2010
Mesenchymal and haematopoietic stem cells form a unique bone marrow nicheSimón Méndez-Ferrer, Tatyana V Michurina, Francesca Ferraro, et al.
HIV Clinical Trials|April 19, 2011
Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, CanadaNisha Andany, Janet M Raboud, Sharon Walmsley, et al.
Lancet (London, England)|December 19, 2006
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trialRodger D MacArthur, Richard M Novak, Grace Peng, et al.
Pageof 16

Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
Cell Reports|November 15, 2018
Thrombopoietin Metabolically Primes Hematopoietic Stem Cells to Megakaryocyte-Lineage DifferentiationAyako Nakamura-Ishizu, Takayoshi Matsumura, Patrick S Stumpf, et al.
AIDS Research and Human Retroviruses|October 13, 2020
Micro RNA Targets in HIV Latency: Insights into Novel Layers of Latency ControlAshley I Heinson, Jeongmin Woo, Amey Mukim, et al.
Frontiers in Immunology|October 7, 2022
Transcriptional programming of immunoregulatory responses in human Langerhans cellsJames Davies, Sofia Sirvent, Andres F Vallejo, et al.
HIV Clinical Trials|February 1, 2005
Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive personsR D MacArthur, L Chen, G Peng, et al.
Pharmacogenetics|April 13, 2000
Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotypeW M O'Neil, R K Drobitch, R D MacArthur, et al.
HIV Clinical Trials|December 17, 2013
Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage studyRodger D Macarthur, Trevor N Hawkins, Stephen J Brown, et al.
Controlled Clinical Trials|April 18, 2001
The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trialR D MacArthur, L Chen, D L Mayers, et al.
Nature|August 13, 2010
Mesenchymal and haematopoietic stem cells form a unique bone marrow nicheSimón Méndez-Ferrer, Tatyana V Michurina, Francesca Ferraro, et al.
HIV Clinical Trials|April 19, 2011
Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, CanadaNisha Andany, Janet M Raboud, Sharon Walmsley, et al.
Lancet (London, England)|December 19, 2006
A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trialRodger D MacArthur, Richard M Novak, Grace Peng, et al.
Pageof 16